<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37369472</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Plasma Exchange in Catastrophic Antiphospholipid Syndrome (CAPS): A Rare Case Report and Literature Review.</ArticleTitle><Pagination><StartPage>1914</StartPage><EndPage>1919</EndPage><MedlinePgn>1914-1919</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21873/invivo.13286</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Catastrophic antiphospholipid syndrome (CAPS) may be the first manifestation ("de novo") of antiphospholipid syndrome (APS) or a complication in the clinical course of patients known to have this syndrome. Approximately 40% of patients had an associated autoimmune disease, mainly, systemic lupus erythematosus (SLE). The trigger can be one of the following: infections, surgical interventions, neoplasms, pregnancy, discontinuation of anticoagulant treatment, and others. CAPS is a medical emergency in which early identification and prompt initiation of aggressive therapy is extremely important. According to the Guidelines for the use of Therapeutic Apheresis in Clinical Practice developed by the American Society for Apheresis (ASFA), last updated in April 2023, in CAPS, the indication for therapeutic plasma exchange (TPE) is category I, grade 2C.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="METHODS">We present a case of probable CAPS secondary to systemic lupus erythematosus (SLE) in an elderly patient in whom clinical and biological improvement was achieved through a multidisciplinary approach and prompt initiation of TPE. Because TPE is considered first-line therapy in CAPS, we initiated the procedure as soon as the attending rheumatologist raised this suspicion. Four plasmapheresis sessions were performed in the Intensive Care Unit. We used TPE by membrane filtration. Following the therapeutic intervention with TPE, corticotherapy (Solumedrol in puls-therapy), cyclophosphamide and anticoagulant treatment, the evolution was favourable, with clinical and biological improvement.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prompt initiation of TPE, because of the suspicion of CAPS, increases the chances of a favourable evolution.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bereanu</LastName><ForeName>Alina-Simona</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania; rares.bereanu@ulbsibiu.ro.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisaltu</LastName><ForeName>Teofil</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bereanu</LastName><ForeName>Rare&#x219;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vintila</LastName><ForeName>Bogdan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codru</LastName><ForeName>Ioana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chicea</LastName><ForeName>Liana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisan</LastName><ForeName>Ovidiu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, "Iuliu Ha&#x21b;ieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#x103;inap</LastName><ForeName>Calin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Iuliu Ha&#x21b;ieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cainap</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Iuliu Ha&#x21b;ieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sava</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, "Lucian Blaga" University of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>County Clinical Emergency Hospital of Sibiu, Sibiu, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002388" MajorTopicYN="N">Catastrophic Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010956" MajorTopicYN="N">Plasmapheresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAPS</Keyword><Keyword MajorTopicYN="N">Catastrophic antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">TPE</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">therapeutic apheresis</Keyword><Keyword MajorTopicYN="N">therapeutic plasma exchange</Keyword></KeywordList><CoiStatement>There are no conflicts of interest related to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37369472</ArticleId><ArticleId IdType="pmc">PMC10347956</ArticleId><ArticleId IdType="doi">10.21873/invivo.13286</ArticleId><ArticleId IdType="pii">37/4/1914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cervantes C, Bloch E, Sperati C. Therapeutic plasma exchange: Core curriculum 2023. American Journal of Kidney Diseases. 2023;81(4):475&#x2013;492. doi: 10.1053/j.ajkd.2022.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2022.10.017</ArticleId><ArticleId IdType="pubmed">36775691</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan A, Connelly-Smith L, Aqui N, Balogun R, Klingel R, Meyer E, Pham H, Schneiderman J, Witt V, Wu Y, Zantek N, Dunbar N, Schwartz G. Guidelines on the use of therapeutic apheresis in clinical practice -evidence- based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. Journal of Clinical Apheresis. 2022;34(3):171&#x2013;354. doi: 10.1002/jca.21705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21705</ArticleId><ArticleId IdType="pubmed">31180581</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77&#x2013;278. doi: 10.1002/jca.22043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.22043</ArticleId><ArticleId IdType="pubmed">37017433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridey JL, Kaplan AA. Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology. UpToDate, 2023. Available at: https://www.uptodate.com/contents/therapeuticapheresis-plasma-exchange-or-cytapheresis-indications-andtechnology. [Last accessed on May 30, 2023]</Citation></Reference><Reference><Citation>Gounder D. Guidelines for the use of therapeutic plasma exchange (TPE) in renal disease. National, Manual(s), Clinical Comp. 2020:pp. 1&#x2013;5.</Citation></Reference><Reference><Citation>Ahmed S, Kaplan A. Therapeutic plasma exchange using membrane plasma separation. Clinical Journal of the American Society of Nephrology. 2023;15(9):1364&#x2013;1370. doi: 10.2215/CJN.12501019.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.12501019</ArticleId><ArticleId IdType="pmc">PMC7480555</ArticleId><ArticleId IdType="pubmed">32312791</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre-Valencia D, Naranjo-Escobar J, Posso-Osorio I, Mac&#xed;a-Mej&#xed;a MC, Nieto-Aristiz&#xe1;bal I, Barrera T, Obando MA, Tob&#xf3;n GJ. Therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases. Autoimmune Dis. 2019;2019:5350960. doi: 10.1155/2019/5350960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5350960</ArticleId><ArticleId IdType="pmc">PMC6432729</ArticleId><ArticleId IdType="pubmed">30984421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bambauer R, Latza R, Bambauer C, Burgard D, Schiel R. Therapeutic apheresis in autoimmune diseases. Open Access Rheumatol. 2013;13(5):93&#x2013;103. doi: 10.2147/OARRR.S34616.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S34616</ArticleId><ArticleId IdType="pmc">PMC5074795</ArticleId><ArticleId IdType="pubmed">27790028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanatta E, Cozzi M, Marson P, Cozzi F. The role of plasma exchange in the management of autoimmune disorders. British Journal of Haematology. 2022;186(2):207&#x2013;219. doi: 10.1111/bjh.15903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15903</ArticleId><ArticleId IdType="pubmed">30924130</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz J, Winters J, Padmanabhan A, Balogun R, Delaney M, Linenberger M, Szczepiorkowski Z, Williams M, Wu Y, Shaz B. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. Journal of Clinical Apheresis. 2021;28(3):145&#x2013;284. doi: 10.1002/jca.21276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21276</ArticleId><ArticleId IdType="pubmed">23868759</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman-Filip C. Therapeutic plasma exchange and double filtration plasmapheresis in severe neuroimmune disorders. Acta Clinica Croatica. 2020;58:621&#x2013;626. doi: 10.20471/acc.2019.58.04.08.</Citation><ArticleIdList><ArticleId IdType="doi">10.20471/acc.2019.58.04.08</ArticleId><ArticleId IdType="pmc">PMC7314295</ArticleId><ArticleId IdType="pubmed">32595246</ArticleId></ArticleIdList></Reference><Reference><Citation>Uthman I, Noureldine M, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2022;78(2):155&#x2013;161. doi: 10.1136/annrheumdis-2018-213846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213846</ArticleId><ArticleId IdType="pubmed">30282668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado MJ. Catastrophic antiphospholipid syndrome (CAPS) Best Pract Res Clin Rheumatol. 2012;26(4):535&#x2013;41. doi: 10.1016/j.berh.2012.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2012.07.005</ArticleId><ArticleId IdType="pubmed">23040365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016;28(3):218&#x2013;227. doi: 10.1097/BOR.0000000000000269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000269</ArticleId><ArticleId IdType="pmc">PMC4958413</ArticleId><ArticleId IdType="pubmed">26927441</ArticleId></ArticleIdList></Reference><Reference><Citation>Legault K, Schunemann H, Hillis C, Yeung C, Akl E, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl J, Moffat K, O&#x2019;Brien S, Pengo V, Rand J, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2023;16(8):1656&#x2013;1664. doi: 10.1111/jth.14192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14192</ArticleId><ArticleId IdType="pubmed">29978552</ArticleId></ArticleIdList></Reference><Reference><Citation>Marson P, Bagatella P, Bortolati M, Tison T, De Silvestro G, Fabris F, Pengo V, Ruffatti A. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. Journal of Internal Medicine. 2021;264(2):201&#x2013;203. doi: 10.1111/j.1365-2796.2008.01942.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2008.01942.x</ArticleId><ArticleId IdType="pubmed">18341530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Pinto I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R, CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies) Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Elsevier. Autoimmun Rev. 2016;15(12):1120&#x2013;1124. doi: 10.1016/j.autrev.2016.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.09.010</ArticleId><ArticleId IdType="pubmed">27639837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Benjume B, Rodriguez-Pinto I, Amigo MC, Erkan D, Shoenfeld Y, Cervera R, Espinosa G. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the &#x201c;CAPS Registry&#x201d;. Autoimmun Rev. 2022;21(4):103055. doi: 10.1016/j.autrev.2022.103055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103055</ArticleId><ArticleId IdType="pubmed">35085802</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwelt C. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Therapeutic Apheresis and Dialysis. 2023;7(2):173&#x2013;182. doi: 10.1046/j.1526-0968.2003.00032.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-0968.2003.00032.x</ArticleId><ArticleId IdType="pubmed">12918940</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasquez-Rimachi V, Palma-Garc&#xed;a L, Pacheco-Barrios K, Alva-D&#xed;az C. Successful treatment of catastrophic antiphospholipid syndrome with therapeutic plasma exchange: a case report. Hematol Transfus Cell Ther. 2020;42(3):287&#x2013;291. doi: 10.1016/j.htct.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.htct.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC7417464</ArticleId><ArticleId IdType="pubmed">31537477</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Sayf A, Virk F, Tatem G. A case of catastrofic antiphospholipid antibody syndrome. Chest J 150. 2016;(4):233. doi: 10.1016/j.chest.2016.08.246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2016.08.246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Pinto I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R, CAPS Registry Project Group The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Br J Rheumatol. 2018;57(7):1264&#x2013;1270. doi: 10.1093/rheumatology/key082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key082</ArticleId><ArticleId IdType="pubmed">29660074</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>